DRTE Dendrite International (MM)

Dendrite International, Inc. (NASDAQ: DRTE), a leading provider of pharmaceutical industry solutions, today announced the launch of a new version of its web based marketing solution, Dendrite Campaign Manager(TM) 6.0 that enables pharmaceutical companies to deliver highly targeted, multi-channel marketing campaigns to prescribers and their patients. These latest advances are possible as a result of Dendrite's recent acquisition of Optas; an important proof point of its strategy to expand its marketing solutions offerings, to equip customers with powerful integrated marketing and sales campaign capabilities rooted in the deepest understanding of patient and physician preferences. Campaign Manager 6.0's built-in functionality enables pharmaceutical marketers to segment and target their customers, generate lists for execution channels, create and deploy emails and surveys, and track campaign effectiveness. The tool's web-based architecture enables marketers to capture opt-in registration information, track multi-segmented campaigns and easily view all campaign activity online. New built-in enhancements to Dendrite Campaign Manager 6.0 include automated privacy compliance features that shield the pharmaceutical marketer from inadvertently discovering or improperly using personally identifiable information during the design and deployment of their marketing initiatives, and to enable strict adherence to US-based federal and state regulations, including HIPAA, CAN SPAM and the even more rigorous European regulations. "When we added Optas to our portfolio of solutions, we gave our customers a way to maximize the effectiveness of their marketing campaigns," said Rick Rose, vice president and general manager, Dendrite Marketing Solutions. "The release of version 6.0 expands our leadership position in this area and provides a tremendous asset to our clients as they look to launch and promote brands on a global basis -- thanks not only to the automation of complex events that allow for greater efficiencies in program management, but also, and more importantly, to the powerful insights obtained through the actionable data derived from this platform." About Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com. Note: Dendrite is a registered trademark of Dendrite International, Inc. This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.